The 2016 EU Drug Markets Report provides a unique insight into the operation of illicit drug markets in the EU. The report assesses the impact of the drug market on society and the factors driving it. It explores the market for cannabis, heroin, cocaine, amphetamines, MDMA and new psychoactive substances. Understanding these hidden markets, and the actors involved, is essential to making sound policy decisions with lasting impact. The report combines the analytical power of the EMCDDA’s drug monitoring system with Europol’s operational intelligence on trends in organised crime.
Two separate publications cover the topic at different levels. The Strategic Overview is a 30-page summary offering easy access to the key findings of the main report. The In-depth Analysis is a comprehensive 188-page report, analysing what is known about the European drug market today.
There are also a number of background papers published alongside the main report.
This is the full report (188 pages) presenting what is known about the EU drug market today.
This 30-page summary offers easy access to the key findings of the main report.
Designed for mobiles and tablets (English only)
The following papers were commissioned by the EMCDDA to provide background information to inform and contribute to the drafting of the 2016 EU Drug Markets Report
Watch these motion graphics and animations for a quick overview of production techniques and trafficking routes.
The 2016 EU Drug Markets Report — In-depth Analysis is being launched at a press conference in Brussels on 5 April by Dimitris Avramopoulos, European Commissioner for Migration, Home Affairs and Citizenship. The Commissioner will be joined by EMCDDA Director Alexis Goosdeel and Europol Director Rob Wainwright.
Press contact: (Spokespersons’ service): Tove Ernst (32) 2 298 67 64; Markus Lammert (32) 2 298 04 23
Experts at the EMCDDA and Europol will be available for interviews (see contacts below):